E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Graft versus Host Disease |
|
E.1.1.1 | Medical condition in easily understood language |
A condition in which the donor immune system recognises the patient's normal cells as 'foreign' and attacks them leading to organ damage |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066261 |
E.1.2 | Term | Chronic graft versus host disease |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the safety and activity (in terms of best overall response within 6 months) of azacitidine in the treatment of patients with cGVHD who have failed therapy with corticosteroids |
|
E.2.2 | Secondary objectives of the trial |
• Best organ level response as determined by improvement and changes in individual organ systems involved in cGvHD • Proportion of patients with a mixed response • Quality of Life (QoL) • Duration of response • Reduction in the dose of corticosteroids
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with moderate or severe cGvHD OR progressive, recurrent or delayed-onset acute GvHD as defined by the NIH Consensus Conference Diagnostic Criteria who have failed therapy with corticosteroids (+/- calcineurin inhibitors). Failure of corticosteroid is defined as either: o progression of cGvHD on 1mg/kg/day prednisolone over 2 weeks o stable cGvHD on ≥0.5mg/kg/day prednisolone over 4 weeks o inability to taper prednisolone below 0.5mg/kg/day without recurrence of clinical manifestations o inability to tolerate first line therapy* (eg steroid myopathy, calcineurin inhibitor-induced renal toxicity) *Patients must have proven steroid toxicity to meet this criterion for having failed corticosteroid therapy. These cases must be discussed with the Chief Investigator prior to trial entry. • Patients must be unable to receive treatment with extracorporeal photophoresis (ECP) therapy (either refractory/intolerant to ECP, lack of ECP availability at local institution or patient/physician preference) • Age ≥16 years of age • Life expectancy of at least 3 months with no imminent relapse expected • Women of childbearing potential and all men must be using adequate birth control measures throughout the study and for a minimum of 3 months following the end of trial treatment • Able to provide written informed consent • Patients must be able to comply with all study procedures |
|
E.4 | Principal exclusion criteria |
• Uncontrolled infection ≥ grade 3 requiring treatment at study entry • Neutrophil count <1x109/L (support with GCSF permitted) • Platelet count <30 x109/L • Known HIV infection • Known hepatitis B or C • ECOG ≥ 3 • Patients with ocular GvHD only • Pulmonary GvHD • Patients receiving active therapy for cGvHD within 14 days of study entry (with the exception of corticosteroids and calcineurin inhibitors) • Any investigational agents within 14 days of study entry • Treatment with ECP within 6 months of study entry • Known hypersensitivity to azacitidine • Women who are pregnant or breastfeeding • Any other condition that in the Investigator's opinion will affect the patient's participation in this trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Best overall response (complete or partial) (GvHD) within 6 months as defined by modified National Institutes of Health (NIH) Consensus Response Criteria
Tolerability of azacitidine defined as the absence of grade 3 or 4 clinically relevant and drug related adverse events (AEs) resulting in stopping treatment early including treatment related deaths within 6 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Within 6 cycles of trial treatment. |
|
E.5.2 | Secondary end point(s) |
Best organ level response (GvHD) as determined by the incremental improvement and changes in individual organ systems involved in cGvHD according to modified NIH Consensus Response Criteria
Proportion of patients with mixed response as defined by modified National Institutes of Health (NIH) Consensus Response Criteria
Quality of Life (QoL)
Duration of response
Reduction in corticosteroid dosage
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Following 6 cycles of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be six months from the last data capture. This will allow sufficient time for the completion of protocol procedures, data collection and input. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 3 |